Celltrion: Understanding Inflectra's U.S. Challenges
Celltrion Inc (068270 KS) 's Inflectra (biosimilar of Remicade marketed in the U.S.) has struggled to gain a foothold in the market since its...
614 Views
Samsung C&T Placement: Finally First Step Towards a Legit Holding Company
I would take this deal. I believe the market will interpret this placement as the starting point of C&T-centered holding company conversion....
486 Views
BBSP ASIA Equity Asia Weekly Research - 19 Sep 2018
THE MAIN IDEA(Relative Value Approach in USD Terms)Long Term Allocation (Strategic view) Relative Value vs MXAP in USD terms⦁ NIKKEI/MXAP: Long...
364 Views
Hyundai Motor Group Restructuring Update - Revised Plan Summary
We had another interesting day yesterday. Samsung made a headline with its jaw-dropping investment size (a total ₩180tril). Samsung Biologics Co.,...
457 Views
Samsung Group Plans to Invest 180 Trillion Won in the Next Three Years
The Samsung Group announced a major plan today to invest 180 trillion won (about US$160 billion) in the next three years, including in major...
346 Views